EP0804596A4 - FUSION PROTEINS WITH CYTOTOXIC ACTIVITY AGAINST CELLS OVEREXPRESSING erbB3 AND/OR erbB4 - Google Patents

FUSION PROTEINS WITH CYTOTOXIC ACTIVITY AGAINST CELLS OVEREXPRESSING erbB3 AND/OR erbB4

Info

Publication number
EP0804596A4
EP0804596A4 EP95937728A EP95937728A EP0804596A4 EP 0804596 A4 EP0804596 A4 EP 0804596A4 EP 95937728 A EP95937728 A EP 95937728A EP 95937728 A EP95937728 A EP 95937728A EP 0804596 A4 EP0804596 A4 EP 0804596A4
Authority
EP
European Patent Office
Prior art keywords
erbb4
erbb3
fusion proteins
activity against
cytotoxic activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP95937728A
Other languages
German (de)
French (fr)
Other versions
EP0804596A1 (en
Inventor
Roger John Daly
Rodney John Fiddes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CRC for Biopharmaceutical Research Pty Ltd
Original Assignee
CRC for Biopharmaceutical Research Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CRC for Biopharmaceutical Research Pty Ltd filed Critical CRC for Biopharmaceutical Research Pty Ltd
Publication of EP0804596A1 publication Critical patent/EP0804596A1/en
Publication of EP0804596A4 publication Critical patent/EP0804596A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
EP95937728A 1994-11-22 1995-11-17 FUSION PROTEINS WITH CYTOTOXIC ACTIVITY AGAINST CELLS OVEREXPRESSING erbB3 AND/OR erbB4 Withdrawn EP0804596A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPM9598A AUPM959894A0 (en) 1994-11-22 1994-11-22 Fusion proteins with cytotoxic activity against cells overexpressing erbb2-4
AUPM9598/94 1994-11-22
PCT/AU1995/000767 WO1996016176A1 (en) 1994-11-22 1995-11-17 FUSION PROTEINS WITH CYTOTOXIC ACTIVITY AGAINST CELLS OVEREXPRESSING erbB3 AND/OR erbB4

Publications (2)

Publication Number Publication Date
EP0804596A1 EP0804596A1 (en) 1997-11-05
EP0804596A4 true EP0804596A4 (en) 2000-03-08

Family

ID=3784109

Family Applications (1)

Application Number Title Priority Date Filing Date
EP95937728A Withdrawn EP0804596A4 (en) 1994-11-22 1995-11-17 FUSION PROTEINS WITH CYTOTOXIC ACTIVITY AGAINST CELLS OVEREXPRESSING erbB3 AND/OR erbB4

Country Status (5)

Country Link
EP (1) EP0804596A4 (en)
JP (1) JPH10509949A (en)
AU (1) AUPM959894A0 (en)
CA (1) CA2205807A1 (en)
WO (1) WO1996016176A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1063185C (en) * 1996-07-04 2001-03-14 尹光环 Heri factor coupled material, its preparation, composition containing it and application
AUPP785098A0 (en) * 1998-12-21 1999-01-21 Victor Chang Cardiac Research Institute, The Treatment of heart disease
US20070197431A1 (en) * 2002-02-21 2007-08-23 Kermit Carraway Novel protein for inhibiting tumor progression and increasing nerve regeneration

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0383599A2 (en) * 1989-02-17 1990-08-22 Merck & Co. Inc. Protein anti-cancer agent
WO1992020798A1 (en) * 1991-05-24 1992-11-26 Genentech, Inc. HEREGULINS (HRGs), BINDING PROTEINS OF P185?erb2¿

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2103323A1 (en) * 1992-11-24 1994-05-25 Gregory D. Plowman Her4 human receptor tyrosine kinase

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0383599A2 (en) * 1989-02-17 1990-08-22 Merck & Co. Inc. Protein anti-cancer agent
WO1992020798A1 (en) * 1991-05-24 1992-11-26 Genentech, Inc. HEREGULINS (HRGs), BINDING PROTEINS OF P185?erb2¿

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
FRIEDMAN P N ET AL: "BR96 SFV-PE40, A POTENT SINGLE-CHAIN IMMUNOTOXIN THAT SELECTIVELY KILLS CARCINOMA CELLS", CANCER RESEARCH,US,AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, vol. 53, no. 2, 15 January 1993 (1993-01-15), pages 334-339, XP000652093, ISSN: 0008-5472 *
GAWLAK S L ET AL: "BASIC FIBROBLAST GROWTH FACTOR-PSEUDOMONAS EXOTOXIN CHIMERIC PROTEINS;COMPARISON WITH ACIDIC FIBROBLAST GROWTH FACTOR-PSEUDOMONAS EXOTOXIN", BIOCONJUGATE CHEMISTRY,US,AMERICAN CHEMICAL SOCIETY, WASHINGTON, vol. 4, no. 6, 1993, pages 483-489, XP000417287, ISSN: 1043-1802 *
HOLMES W E ET AL: "IDENTIFICATION OF HEREGULIN, A SPECIFIC ACTIVATOR OF P185ERB2", SCIENCE,US,AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, vol. 256, 22 May 1992 (1992-05-22), pages 1205-1210, XP002002186, ISSN: 0036-8075 *
JESCHKE M ET AL: "TARGETED INHIBITION OF TUMOR-CELL GROWTH BY RECOMBINANT HEREGULIN- TOXIN FUSION PROTEINS", INTERNATIONAL JOURNAL OF CANCER,US,NEW YORK, NY, vol. 60, no. 5, 3 March 1995 (1995-03-03), pages 730-739, XP000571537, ISSN: 0020-7136 *
PLOWMAN ET AL: "Ligand-specific activation of HER4/p180erbB4, a fourth member of the epidermal growth factor receptor family", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA,US,NATIONAL ACADEMY OF SCIENCE. WASHINGTON, vol. 90, March 1993 (1993-03-01), pages 1746-1750, XP002090525, ISSN: 0027-8424 *
See also references of WO9616176A1 *
SIEGALL C. B. ET AL.: "Activity of HER4-targeted ligand-toxin fusion proteins against human tumors.", PROC. AMERICAN ASSOC. CANCER RES., vol. 35, March 1994 (1994-03-01), pages 382, XP002127063 *
SIEGALL C.B. ET AL.: "HER4 expression correlated with cytotoxicity directed by a heregulin-toxin fusion protein", J. BIOL. CHEM., vol. 270, no. 13, 31 March 1995 (1995-03-31), pages 7625 - 7630, XP002004424 *
TZAHAR E ET AL: "ERBB-3 AND ERBB-4 FUNCTION AS THE RESPECTIVE LOW AND HIGH AFFINITY RECEPTORS OF ALL NEU DIFFERENTIATION FACTOR/HEREGULIN ISOFORMS", JOURNAL OF BIOLOGICAL CHEMISTRY,US,AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, vol. 269, no. 40, 7 October 1994 (1994-10-07), pages 25226-25233, XP002004421, ISSN: 0021-9258 *
WELS W ET AL: "SELECTIVE INHIBITION OF TUMOR CELL GROWTH BY A RECOMBINANT SINGLE-CHAIN ANTIBODY-TOXIN SPECIFIC FOR THE ERBB-2 RECEPTOR", CANCER RESEARCH,US,AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, vol. 52, no. 22, 15 November 1992 (1992-11-15), pages 6310-6317, XP000647735, ISSN: 0008-5472 *

Also Published As

Publication number Publication date
WO1996016176A1 (en) 1996-05-30
CA2205807A1 (en) 1996-05-30
AUPM959894A0 (en) 1994-12-15
JPH10509949A (en) 1998-09-29
EP0804596A1 (en) 1997-11-05

Similar Documents

Publication Publication Date Title
GB2221300B (en) Enzyme electrodes and improvements in the manufacture thereof
EP0795007A4 (en) Bioengineered human blood cells
HUP9901640A3 (en) Protein with phospholipase activity
EP0745670A4 (en) Stabilized transglutaminase and enzymatic preparation containing the same
IL113708A0 (en) Protein production and protein delivery
IL94243A0 (en) Fusion polypeptide and its preparation
AU2527397A (en) Fas ligand fusion proteins and their uses
HUP9900323A2 (en) Recombinant protein having bacteriophage endosialidase enzymatic activity
IL85372A0 (en) Peptides with laminin-like activity
GB9705903D0 (en) VP22 Proteins and uses thereof
ZA899161B (en) Recombinant proteins with adipsin and complement d activities
AU3594395A (en) Gold pan with flukes and stratifiers
EP0298645A3 (en) Polypeptide possessing maltotetraose-forming amylase activity, and its uses
ZA9410217B (en) Recombinant human thymopoietin proteins and uses therefor.
AU4030697A (en) Proteins having telomerase activity
IL108156A0 (en) An enzyme with polygalacturonase activity
EP0804596A4 (en) FUSION PROTEINS WITH CYTOTOXIC ACTIVITY AGAINST CELLS OVEREXPRESSING erbB3 AND/OR erbB4
EP0700999A3 (en) Expression systems utilizing autolyzing fusion proteins and a novel reducing polypeptide
HK1002961A1 (en) Bacterial protein with xylanase activity.
HUT54932A (en) Shear insert and insert-holding arrangement
GB9423372D0 (en) Proteins and their uses
EP0683229A3 (en) Process for the preparation of recombinant aprotinin and recombinant aprotinin variants with natural N-terminal sequence.
ZA9510154B (en) Chimeric proteins having fibrinolytic and thrombin-inhibing properties
IL110892A (en) Recombinant alpha-galactosidase enzyme methods for the production thereof and methods for utilizing the same
AU3864795A (en) Fusion proteins with cytotoxic activity against cells overexpressing erbB2-4

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19970619

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20000121

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20000601